Genscript Biotech saw the highest growth of 399% in patent filings and 299% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 399% and grants by 299%. GlobalData’s DataBook provides a comprehensive analysis of Genscript Biotech‘s patent filings and grants. Buy the databook here.
Genscript Biotech has been focused on protecting inventions in European Patent Office(EPO) with eight publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 29% filings and 0% grants. The European Patent Office(EPO), Australia(AU), China(CN), and United States(US) patent Office are among the top ten patent offices where Genscript Biotech is filings its patents. Among the top granted patent authorities, Genscript Biotech has 33% of its grants in South Africa(ZA), 11% in Australia(AU) and 11% in United States(US).
Patents related to cell & gene therapy and rare diseases lead Genscript Biotech's portfolio
Genscript Biotech has the highest number of patents in cell & gene therapy followed by, rare diseases and immuno-oncology. For cell & gene therapy, nearly 60% of patents were filed and no patents were granted in Q4 2023.
Cell therapy related patents lead Genscript Biotech portfolio followed by multiple myeloma (kahler disease), and sweeteners
Genscript Biotech has highest number of patents in cell therapy followed by multiple myeloma (kahler disease), sweeteners, dairy & soy food, and fermented milk.
For comprehensive analysis of Genscript Biotech's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.